ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Roma, Lazio

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Roma, Lazio, ITA:

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (DUO-O)

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Durvalumab placebo
Drug: Bevacizumab

Phase 3

AstraZeneca
AstraZeneca

Roma, Italy and 213 other locations

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Olaparib 300mg tablets
Drug: Placebo to match olaparib 300mg

Phase 3

AstraZeneca
AstraZeneca

Roma, Italy and 125 other locations

of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...

Active, not recruiting
Ovarian Cancer
Drug: Alpelisib
Drug: Pegylated liposomal doxorubicin (PLD)

Phase 3

Novartis
Novartis

Roma, RM, Italy and 93 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Roma, Italy and 176 other locations

This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian...

Active, not recruiting
Recurrent Ovarian Cancer
Recurrent Primary Peritoneal Carcinoma
Drug: Relacorilant, 100mg QD
Drug: Relacorilant, 150mg QD

Phase 2

Corcept Therapeutics
Corcept Therapeutics

Roma, Italy and 20 other locations

in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian...

Enrolling
Primary Peritoneal Cancer
Fallopian Tube Cancer
Biological: Pembrolizumab
Biological: Nemvaleukin

Phase 3

Mural Oncology

Rome, Italy and 131 other locations

This is a single arm phase II, multicenter study evaluating Pembrolizumab in recurrent platinum resistant CPS score \>1 positive ovarian, Fa...

Enrolling
Fallopian Tube Cancer
Ovarian Cancer
Drug: Pembrolizumab

Phase 2

Institute of Hospitalization and Scientific Care (IRCCS)

Rome, Italy

of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with hig...

Active, not recruiting
Peritoneal Cancer
Fallopian Tube Cancer
Drug: Mirvetuximab soravtansine

Phase 2

ImmunoGen
ImmunoGen

Roma, Italy and 77 other locations

Randomized phase 3 trial evaluating niraparib plus dostarlimab vs chemotherapy at physician's choice in the treatment of recurrent ovarian, ...

Enrolling
Ovarian Cancer
Drug: Bevacizumab
Drug: Topotecan

Phase 3

Institute of Hospitalization and Scientific Care (IRCCS)

Rome, Italy and 7 other locations

of REGN4018 can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus* The study will ...

Enrolling
Recurrent Primary Peritoneal Cancer
Recurrent Ovarian Cancer
Drug: REGN4018
Drug: Sarilumab

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Roma, Lazio, Italy and 49 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems